Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Reardon

Showing results (71-80 of 404) with videos related to

Pageof 41
Sort By:
Neuro-Oncology|October 15, 2014
Impact of imaging measurements on response assessment in glioblastoma clinical trialsDavid A Reardon, Karla V Ballman, Jan C Buckner, et al.
Journal of Neuro-Oncology|October 23, 2012
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine modelStephen T Keir, Henry S Friedman, David A Reardon, et al.
Neuro-Oncology|February 28, 2015
Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastomaKelong Han, Melanie Ren, Wolfgang Wick, et al.
Neuro-Oncology|December 17, 2013
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trialsKelong Han, Melanie Ren, Wolfgang Wick, et al.
Future Oncology (London, England)|March 23, 2011
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignanciesDavid A Reardon, Bart Neyns, Michael Weller, et al.
Future Oncology (London, England)|April 26, 2018
Bevacizumab biosimilars: scientific justification for extrapolation of indicationsBarbara Melosky, David A Reardon, Andrew B Nixon, et al.
Cancer|September 30, 2014
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversiesKathryn M Field, Justin T Jordan, Patrick Y Wen, et al.
Current Oncology Reports|December 3, 2010
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatmentsEvanthia Galanis, Wenting Wu, Jann Sarkaria, et al.
Neuroradiology|January 11, 2017
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastomaLei Qin, Xiang Li, Amanda Stroiney, et al.
Nature Reviews. Clinical Oncology|July 5, 2017
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cellsHui K Gan, Martin van den Bent, Andrew B Lassman, et al.
Pageof 41

Showing results (71-80 of 404) with videos related to

Sort By:
Pageof 41
Neuro-Oncology|October 15, 2014
Impact of imaging measurements on response assessment in glioblastoma clinical trialsDavid A Reardon, Karla V Ballman, Jan C Buckner, et al.
Journal of Neuro-Oncology|October 23, 2012
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine modelStephen T Keir, Henry S Friedman, David A Reardon, et al.
Neuro-Oncology|February 28, 2015
Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastomaKelong Han, Melanie Ren, Wolfgang Wick, et al.
Neuro-Oncology|December 17, 2013
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trialsKelong Han, Melanie Ren, Wolfgang Wick, et al.
Future Oncology (London, England)|March 23, 2011
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignanciesDavid A Reardon, Bart Neyns, Michael Weller, et al.
Future Oncology (London, England)|April 26, 2018
Bevacizumab biosimilars: scientific justification for extrapolation of indicationsBarbara Melosky, David A Reardon, Andrew B Nixon, et al.
Cancer|September 30, 2014
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversiesKathryn M Field, Justin T Jordan, Patrick Y Wen, et al.
Current Oncology Reports|December 3, 2010
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatmentsEvanthia Galanis, Wenting Wu, Jann Sarkaria, et al.
Neuroradiology|January 11, 2017
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastomaLei Qin, Xiang Li, Amanda Stroiney, et al.
Nature Reviews. Clinical Oncology|July 5, 2017
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cellsHui K Gan, Martin van den Bent, Andrew B Lassman, et al.
Pageof 41